

3762
41

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

RECEIVED
DEC 06 2004
OFFICE OF PETITIONS

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
DEC 06 2004

on November 22, 2004

Date

TECHNOLOGY CENTER R3700


Geraldine Gress

Reed Smith LLP
599 Lexington Avenue
29th Floor
New York, New York 10022-7650
Tel: 212-521-5400; Fax: 212-521-5450

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Applicant: Nissim DARVISH, et al.
Serial No: 09/914,889
Filing Date: January 24, 2002
For: Blood Glucose Level Control
Enclosures: (1) Transmittal of IDS (3 pages); (2) Sixth Supplementary Information Disclosure Statement (2 pages); (3) Certification Under 37 CFR 1.97(e) (1 page); (4) IDS Citation (1 page), Search Report & one reference; (5) Acknowledgement Postcard.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



015/02367

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Nissim DARVISH, et al.

Serial No: 09/914,889

Group Art Unit: 3762

Filing Date: January 24, 2002

Examiner: JASTRZAB, Jeffrey

For: BLOOD GLUCOSE LEVEL CONTROL

SIXTH SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

DEC 06 2004

RECEIVED
DEC 08 2004
OFFICE OF PETITIONS

Sir:

TECHNOLOGY CENTER R3700

Applicants respectfully direct the attention of the Examiner to additional art cited with respect to U.S. Application No. 09/914,889 which is a U.S. national phase filing of PCT application No. PCT/IL00/00132. The present application is also a continuation-in-part of US Application No. 09/481,253, now US patent 6,571,127, which is a continuation of PCT/IL97/00243.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP 2001.06, MPEP 1893.03(e) and MPEP 1893.03(g) and to indicate in the next office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is an Equivalent to Form PTO-1449 listing the cited art. Also attached are copies¹ of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.


¹ To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.

In accordance with MPEP Section 609 it is requested that each document cited [including any mentioned in Applicants' specification which is not repeated on the attached (or prior) PTO-1449 form(s) or equivalent(s)] be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form or equivalents thereof, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37CFR 1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,
Nissim DARVISH, et al.




Maier FENSTER,
Registration No. 41,016

November 7, 2004

William H. Dippert, Esq.
Reed Smith LLP
599 Lexington Avenue, 29th Floor
New York, NY 10022-7650

Tel: (212) 521-5400



5/02367

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Nissim DARVISH, et al.

Serial No: 09/914,889

Group Art Unit: 3762

Filing Date: January 24, 2002

Examiner: JASTRZAB, Jeffrey R.

For: BLOOD GLUCOSE LEVEL CONTROL

CERTIFICATION UNDER 37 CFR 1.97(e)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

DEC 06 2004

TECHNOLOGY CENTER R3700

Sir:

This is to certify that each item of information contained in the attached Supplementary Information Disclosure Statement was first cited in a Search Report from a foreign patent office in a counterpart foreign application, no. PCT/IL03/00736, not more than three months prior to the filing of the statement.

Enclosed is a copy of the Search Report dated September 13, 2004 from the foreign patent office, clearly showing that the Information Disclosure Statement is being submitted within 3 month of the date of the Search Report.

The Examiner is respectfully requested to review the art in accordance with 37 C.F.R. §1.97(e).

Respectfully submitted,
Nissim DARVISH, et al.

Maier Fenster, Reg. No. 41,016

November 7, 2004

William H. Dippert, Esq.
Reed Smith LLP
599 Lexington Avenue, 29th Floor
New York, NY 10022-7650
Tel: (212) 521-5400

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

015/02367

In Re Application Of: Nissim DARVISH, et al.

Application No.

09/914,889

Filing Date

January 24, 2002

Examiner

JASTRZAB, Jeffrey R

Customer No.

44909

Group Art Unit

3762

Confirmation No.

6006

Title: BLOOD GLUCOSE LEVEL CONTROL

RECEIVED
DEC 06 2004
OFFICE OF PETITIONS

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**37 CFR 1.97(b)**

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☒ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).**RECEIVED**

DEC 06 2004

TECHNOLOGY CENTER R3700

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 015/02367	
In Re Application: Nissim DARVISH, et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
09/914,889	January 24, 2002	JASTRZAB, Jeffrey R	44909	3762	6006	
Title: BLOOD GLUCOSE LEVEL CONTROL						
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))						
<input type="checkbox"/> A check in the amount of _____ is attached.						
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 03-3419 as described below.						
<input type="checkbox"/> Charge the amount of _____						
<input checked="" type="checkbox"/> Credit any overpayment.						
<input checked="" type="checkbox"/> Charge any additional fee required.						
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.						
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
Certificate of Transmission by Facsimile*				Certificate of Mailing by First Class Mail		
I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)				I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____		
_____ (Date)				_____ (Date)		
_____ Signature				_____ Signature of Person Mailing Correspondence		
_____ Typed or Printed Name of Person Signing Certificate				_____ Typed or Printed Name of Person Mailing Certificate		
*This certificate may only be used if paying by deposit account.						
_____ Signature				Dated: November 7, 2004		
Maier Fenster, Reg. No. 41,016						
William H. Dippert, Esq. Reed Smith LLP 599 Lexington Avenue, 29th floor New York, NY 10022-7650 Tel: (212) 521-5400 CC:						